Qualmann C, Nauck M A, Holst J J, Orskov C, Creutzfeldt W
Department of Medicine, Georg-August-University, Göttingen, Germany.
Acta Diabetol. 1995 Mar;32(1):13-6. doi: 10.1007/BF00581038.
GLP-1 (7-36 amide) stimulates insulin and suppresses glucagon secretion in normal subjects and may, in pharmacological doses, normalize hyperglycaemia in type 2 diabetic patients. It is not known whether such pharmacological doses can actually lower blood glucose to hypoglycaemic levels. Therefore, in seven normal fasting subjects, GLP-1 (7-36 amide) was infused intravenously at 0.3, 0.9 and 2.7 pmol/kg per min for 30 min each. The plasma concentration of GLP-1 (7-36 amide) increased dose-dependently, but insulin secretion (insulin, C-peptide) was stimulated only marginally. Glucagon was slightly suppressed, and plasma glucose was reduced, but not into the hypoglycaemia range. In conclusion, when plasma glucose concentrations are in the normal fasting range, GLP-1 (7-36 amide) is not able to stimulate insulin secretion to a degree that causes hypoglycaemia. This should limit the risk of hypoglycaemic responses when GLP-1 (7-36 amide) is administered in pharmacological doses to reduce hyperglycaemia in type 2 diabetic patients.
胰高血糖素样肽-1（7-36酰胺）可刺激正常受试者的胰岛素分泌并抑制胰高血糖素分泌，且在药理剂量下可能使2型糖尿病患者的高血糖恢复正常。目前尚不清楚这种药理剂量是否真能将血糖降至低血糖水平。因此，对7名正常空腹受试者，以每分钟0.3、0.9和2.7 pmol/kg的剂量静脉输注胰高血糖素样肽-1（7-36酰胺），每次输注30分钟。胰高血糖素样肽-1（7-36酰胺）的血浆浓度呈剂量依赖性增加，但胰岛素分泌（胰岛素、C肽）仅受到轻微刺激。胰高血糖素略有抑制，血浆葡萄糖降低，但未降至低血糖范围。总之，当血浆葡萄糖浓度处于正常空腹范围时，胰高血糖素样肽-1（7-36酰胺）无法刺激胰岛素分泌至导致低血糖的程度。这应会限制在以药理剂量给予胰高血糖素样肽-1（7-36酰胺）以降低2型糖尿病患者高血糖时发生低血糖反应的风险。
